WAM
NBIX icon

Weiss Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Weiss Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,910
Closed -$263K – 376
2024
Q1 		$263K Sell
1,910
-12,586
-87% -$1.72M 0.01% 245
2023
Q4 		$1.91M Buy
+14,496
New +$1.67M 0.09% 109
2022
Q4 		– Sell
-3,500
Closed -$372K – 619
2022
Q3 		$372K Buy
+3,500
New +$355K 0.01% 547
2018
Q4 		– Sell
-7,865
Closed -$967K – 477
2018
Q3 		$967K Hold
7,865
– – 0.07% 100
2018
Q2 		$773K Hold
7,865
– – 0.08% 101
2018
Q1 		$652K Hold
7,865
– – 0.05% 107
2017
Q4 		$610K Buy
7,865
+4,358
+124% +$297K 0.05% 106
2017
Q3 		$215K Buy
+3,507
New +$185K 0.02% 90

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return